- Home
- SEAT vs MGNX Comparison
SEAT vs MGNX Comparison
Compare SEAT & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEAT
- MGNX
- Stock Information
- Founded
- SEAT 2001
- MGNX 2000
- Country
- SEAT United States
- MGNX United States
- Employees
- SEAT N/A
- MGNX N/A
- Industry
- SEAT Industrial Machinery/Components
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- SEAT Industrials
- MGNX Health Care
- Exchange
- SEAT Nasdaq
- MGNX Nasdaq
- Market Cap
- SEAT 96.5M
- MGNX 99.7M
- IPO Year
- SEAT N/A
- MGNX 2013
- Fundamental
- Price
- SEAT $13.29
- MGNX N/A
- Analyst Decision
- SEAT Buy
- MGNX Hold
- Analyst Count
- SEAT 9
- MGNX 6
- Target Price
- SEAT $52.00
- MGNX $3.20
- AVG Volume (30 Days)
- SEAT 111.0K
- MGNX 614.2K
- Earning Date
- SEAT 11-06-2025
- MGNX 11-04-2025
- Dividend Yield
- SEAT N/A
- MGNX N/A
- EPS Growth
- SEAT N/A
- MGNX N/A
- EPS
- SEAT N/A
- MGNX N/A
- Revenue
- SEAT $694,007,000.00
- MGNX $165,495,000.00
- Revenue This Year
- SEAT N/A
- MGNX N/A
- Revenue Next Year
- SEAT N/A
- MGNX N/A
- P/E Ratio
- SEAT N/A
- MGNX N/A
- Revenue Growth
- SEAT N/A
- MGNX 303.47
- 52 Week Low
- SEAT $13.50
- MGNX $0.99
- 52 Week High
- SEAT $100.00
- MGNX $5.10
- Technical
- Relative Strength Index (RSI)
- SEAT 38.55
- MGNX 51.75
- Support Level
- SEAT $14.66
- MGNX $1.69
- Resistance Level
- SEAT $15.45
- MGNX $1.83
- Average True Range (ATR)
- SEAT 1.00
- MGNX 0.11
- MACD
- SEAT -0.46
- MGNX 0.00
- Stochastic Oscillator
- SEAT 6.72
- MGNX 60.00
About SEAT Vivid Seats Inc.
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale. Marketplace segment, act as an intermediary between ticket buyers, sellers, and partners through which company earn revenue from processing ticket sales for live events and facilitating the booking of hotel rooms and packages on websites and mobile applications. Resale segment provides internal research and development support for Skybox and supplements ongoing efforts to deliver software and tools. Majority of revenue is from Marketplace segment.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.